Outcomes in CR
. | . | . | Median time from CR date to most recent CBC in patients remaining in first CR, mo. . | No. first CR rates, by date of most recent CBC* . | . | . | ||
|---|---|---|---|---|---|---|---|---|
| Patients . | No. CRs . | No. relapses . | . | 1-2 y from CR . | 2-3 y from CR . | 3-4 year from CR . | ||
| All | 39 | 3 | 16 | 12 | 8 | 1 | ||
| Low risk | 24 | 0 | 15 | 9 | 4 | 0 | ||
| High risk | 15 | 3 | 20 | 3 | 4 | 1 | ||
. | . | . | Median time from CR date to most recent CBC in patients remaining in first CR, mo. . | No. first CR rates, by date of most recent CBC* . | . | . | ||
|---|---|---|---|---|---|---|---|---|
| Patients . | No. CRs . | No. relapses . | . | 1-2 y from CR . | 2-3 y from CR . | 3-4 year from CR . | ||
| All | 39 | 3 | 16 | 12 | 8 | 1 | ||
| Low risk | 24 | 0 | 15 | 9 | 4 | 0 | ||
| High risk | 15 | 3 | 20 | 3 | 4 | 1 | ||
Low risk was defined as having an initial WBC count below 10 × 109/L; high risk, as having an initial WBC count above 10 × 109/L. Two high-risk patients had simultaneous molecular and clinical relapses, each at 9 months; one patient had molecular followed by clinical relapse, at 12 and 15 months, respectively.
In 12 patients, the most recent CBC was obtained 1 to 2 years from CR date; in an additional 8 patients, the most recent CBC was obtained 2 to 3 years from CR date; and in a final patient the interval between CR date and most recent CBC is 3 to 4 years.